For patients with stage IV non‐small‐cell lung cancer (NSCLC), the mutation status of driver genes (EGFR, ALK, ROS1, etc.)is the best predictor of the efficacy of targeted therapy. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.